Fig. 6: HER2 evolution from baseline biopsy to residual disease after NAT.
Absolute numbers and percentages are reported.
Fig. 6: HER2 evolution from baseline biopsy to residual disease after NAT. | npj Precision Oncology
Absolute numbers and percentages are reported.
